The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.
about
Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic LeukemiaThe clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.Controlling cytomegalovirus: helping the immune system take the leadFraming expectations in early HIV cure research.Progress toward curing HIV infections with hematopoietic stem cell transplantation.Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis.HIV-specific CD8⁺ T cells and HIV eradicationA Critical Care and Transplantation-Based Approach to Acute Respiratory Failure after Hematopoietic Stem Cell Transplantation in Children.Cytomegalovirus-specific T-cell therapies: current status and future prospects.The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients.Primary Immune Deficiency Treatment Consortium (PIDTC) update.T-cell therapies for HIV: Preclinical successes and current clinical strategies.Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy.Broad spectrum antiviral T cells for viral complications after hematopoietic stem cell transplantation.Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood.A survey of infectious disease clinical practices among pediatric blood and marrow transplant programs in the United States.Unrelated Donor Transplantation in Children with Thalassemia Using Reduced Intensity Conditioning - the URTH Trial.Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise.Robust Production of Cytomegalovirus pp65-Specific T Cells Using a Fully Automated IFN-γ Cytokine Capture System.CRISPR therapeutic tools for complex genetic disorders and cancer (Review).Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
P2860
Q26740588-8565207C-030C-41A2-9F87-28429326783DQ33734872-207D92FF-7702-4853-8428-C653822F1FFFQ33820695-52266AF0-7557-4AA5-9EA0-10A3E773AEAAQ34363988-BFD36367-8517-46CF-8953-B7E6C840D04EQ34974480-E2657571-C6F5-4721-A166-8E0E41138FD4Q35104509-FEF7404C-9E86-4553-9DD7-2A1A16DA46ECQ35591430-221413E8-0E7E-466E-8D0A-5FF1C19955D9Q35776868-99EEE779-003D-4CD6-A4B9-75DB81FA0B63Q35917978-A79EC38F-0284-4321-B092-41147F43DC61Q36515071-4F2C09D9-900B-4E54-BF09-B5092745CCEBQ37276584-994E0A69-916C-450E-A083-B6A8B4249E32Q38365044-DFCE5765-4115-484A-837D-26FBD01921A2Q38547042-466ADF9D-0C6A-4A5A-98AC-4FDECAC618FEQ38735833-2A2C0434-AF84-4982-B063-9C662440BDACQ38779846-B88A0EA1-75A5-47F4-B3B9-1A6ACDD7AE84Q38803361-1F524738-CB71-4D91-AAAF-556FFCE6B42CQ38829076-B9314B42-735D-474A-83D2-7186D1D47868Q38855061-EDB51124-AD53-4933-9D81-E8087FB3899AQ38856090-200C2CA0-FCC8-428E-82E3-789A661A826BQ39716725-36A66E91-3A09-4BD5-82A3-401139837DFDQ40253951-4886D6CE-2A1C-4A9E-A11C-C071E5F28E22Q40859295-39C91CBF-256B-424C-BD2B-4A5A8ABE3E58Q41217417-D1673708-FCD3-417C-B2B4-F6E13E6205C3Q41564706-8CE9D53C-FEF3-46A7-AFF0-E771C27E1C45Q47548575-E959E45A-8277-43A5-8DB5-2FDD5C24DAEEQ50057949-FACEC567-552C-419A-9427-0BC5D7E7D516Q50446117-B15D3CE5-3310-4142-BB3B-AF03F2B5AD45Q51733175-B96C87F3-16BE-48FC-9CA4-99F30E5C3BBEQ55383943-BFBBF9BC-A9A1-4A56-8389-1C3AF5F26956Q57176933-98CB5715-151A-48FA-852C-73F1156FDFD4
P2860
The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The time is now: moving toward ...... ation as the standard of care.
@en
The time is now: moving toward ...... ation as the standard of care.
@nl
type
label
The time is now: moving toward ...... ation as the standard of care.
@en
The time is now: moving toward ...... ation as the standard of care.
@nl
prefLabel
The time is now: moving toward ...... ation as the standard of care.
@en
The time is now: moving toward ...... ation as the standard of care.
@nl
P2860
P1433
P1476
The time is now: moving toward ...... ation as the standard of care.
@en
P2093
Catherine M Bollard
Patrick J Hanley
P2860
P304
P356
10.1016/J.JCYT.2013.11.010
P577
2014-02-01T00:00:00Z